A phase II study to investigate the efficacy of PDS 0101 in late-stage cervical intra-epithelial neoplasia
Latest Information Update: 23 Sep 2019
Price :
$35 *
At a glance
- Drugs PDS 0101 (Primary)
- Indications Cervical intraepithelial neoplasia
- Focus Therapeutic Use
- 19 Sep 2019 According to a PDS Biotechnology Corporation media release, this study is expected to start in the first quarter of 2020
- 09 Feb 2016 According to PDS Biotechnology media release, this trial is expected to initiate in 2016 and 2017.
- 29 May 2015 New trial record